BCR-ABL+ leukemias have provided and continue to provide information on the concepts of oncogenic and non-oncogenic addiction, and also have allowed the identification of a number of targetable mechanisms of resistance to existing targeted therapies41,46. This evidence concerns the gene ABL1 and leukemia.